Sign inJoin free

Watch / Small Cap

Two stocks juiced by Team America | DroneShield goes to space | PYC & the FDA

2 Aug 202329:10

Two stocks juiced by Team America | DroneShield goes to space | PYC & the FDA

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Stephen Wood from Eiger Capital discusses the impact of green tech deals on Australian markets. The developments of Patriot Battery Metals (PMT) and Lynas are under discussion. The analysis includes considerations of JGB yields and implications for US Treasuries. The focus is on Lynas's onshoring strategy, emphasising rare earth refining and military applications. The discussion also highlights business diversification through production expansion in Kalgoorlie and Texas.

Oleg Vornik, CEO of DroneShield (DRO), discusses the launch of a satellite-based anti-drone system. The system aims to counter drone threats and has defense and intelligence applications. The company has received its first R&D order for satellite denial systems, enhancing its counter-drone offerings. DroneShield's momentum and significant contracts contribute to its growth in the expanding drone defense industry, as drones gain prominence in both military and civilian applications, including U.S. Department of Defense deployment plans. Operational scaling and competition remain key challenges for the company's expansion

Dr Rohan Hockings, Chief Executive of PYC Therapeutics (PYC), discusses the significance of receiving fast track designation from the FDA for the company's lead drug candidate targeting a blinding eye disease. As a precision medicine maker focused on genetic diseases, PYC aims to address unmet needs. The FDA's recognition accelerates the drug's development timeline, potentially leading to accelerated approval with a shorter clinical pathway. Despite challenges in funding sentiment, PYC remains well-funded and is advancing multiple drugs through clinical development, with a promising pipeline expansion.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy